(MedPage Today) — An investigational antifungal was associated with clinical improvements in a majority of patients with disseminated coccidioidomycosis (DCM) who failed standard treatments, according to an open-label phase IIb trial.
Among 41…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
